Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) FCF Margin (2021 - 2025)

Historic FCF Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 30144.19%.

  • SAB Biotherapeutics' FCF Margin changed N/A to 30144.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 60134.31%, marking a year-over-year increase of 626831100.0%. This contributed to the annual value of 2618.65% for FY2024, which is 14879400.0% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' FCF Margin is 30144.19%.
  • In the past 5 years, SAB Biotherapeutics' FCF Margin registered a high of 30144.19% during Q3 2025, and its lowest value of 8358.96% during Q4 2024.
  • Its 5-year average for FCF Margin is 1587.76%, with a median of 86.0% in 2022.
  • As far as peak fluctuations go, SAB Biotherapeutics' FCF Margin tumbled by -56756300bps in 2023, and later surged by 140673200bps in 2025.
  • Over the past 5 years, SAB Biotherapeutics' FCF Margin (Quarter) stood at 65.47% in 2021, then fell by -18bps to 77.41% in 2022, then tumbled by -5624bps to 4430.85% in 2023, then crashed by -89bps to 8358.96% in 2024, then skyrocketed by 461bps to 30144.19% in 2025.
  • Its last three reported values are 30144.19% in Q3 2025, 11114.37% for Q2 2025, and 11208.53% during Q1 2025.